Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Bilateral sensorineural hearing loss with an active decline in hearing in one ear~* No audiometric improvement with 28-30 days of oral prednisone or other corticosteroid, including an initial dose of 60mg per day for 14 days~* Enrollment within 14 days of completion of corticosteroid therapy~* Age 13 years and older~* No evidence of neutropenia (low white blood cell count)~* No evidence of retrocochlear pathology (ie. acoustic neuroma/vestibular schwannoma)~* May have concurrent, systemic autoimmune disease~Exclusion Criteria:~* Age over 75, or less than 13~* Neutropenia~* Renal insufficiency~* Pregnant females~* Unilateral hearing loss~* Patients with any immunodeficiency syndrome~* Patients receiving methotrexate or any TNF (tumor necrosis factor) antagonist therapy~* Patients with chronic infections~* Patients treated for a malignancy within the past 3 years~* Patients with a latex allergy~* Patients with an inner ear anomaly~* Patients with retrocochlear pathology

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm-Open Label (Type: EXPERIMENTAL): Single Arm-Open Label use of Anakinra

Based on this trial design, predict the completion outcome and termination type (if applicable).